Edition:
United States

Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

504.15INR
6:15am EDT
Change (% chg)

Rs12.55 (+2.55%)
Prev Close
Rs491.60
Open
Rs492.00
Day's High
Rs506.00
Day's Low
Rs488.00
Volume
220,292
Avg. Vol
200,082
52-wk High
Rs621.90
52-wk Low
Rs459.50

CIPL.BO

Chart for CIPL.BO

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.48
Market Cap(Mil.): Rs393,348.19
Shares Outstanding(Mil.): 804.56
Dividend: 2.00
Yield (%): 0.41

Financials

  CIPL.BO Industry Sector
P/E (TTM): 39.14 14.27 17.41
EPS (TTM): 12.49 -- --
ROI: 6.90 -7.17 -5.42
ROE: 8.37 -6.63 -4.68

India's Cipla lowers bio drugs investment, sharpens focus on respiratory

MUMBAI Cipla Ltd , India's fifth-largest drugmaker by sales, plans to reduce investment in biosimilars to sharpen its focus on building a portfolio of high-margin respiratory products, the company's chief executive said on Thursday.

May 25 2017

UPDATE 1-India's Cipla lowers bio drugs investment, sharpens focus on respiratory

* Posts Q4 loss vs. analysts' forecast for profit (Recasts with CEO's comments)

May 25 2017

Indian drugmaker Cipla narrows loss in Jan-March, misses forecasts

MUMBAI, May 25 Cipla Ltd, India's fifth-largest drugmaker by sales, reported a smaller quarterly loss for January-March, but missed expectations of a profit for the period.

May 25 2017

BRIEF-India's Cipla March-qtr loss narrows

* Consol march quarter total income from operations 35.82 billion rupees

May 25 2017

BRIEF-Cipla U.S. arm signs worldwide licensing deal with MEDRx

* Medrx is eligible to receive up to USD 30 million cumulatively through upfront and developmental, regulatory, and commercial milestones payments

Apr 06 2017

BRIEF-Medrx signs drug development and sale contract with Cipla USA Inc

* Says the company enters into a license contract with an India-based pharma Cipla Ltd's wholly owned US-based unit Cipla USA Inc, on development and sale of MRX-4TZT, transdermal patch for the treatment of spastic paralysis

Apr 06 2017

BRIEF-Cipla launches Hepatitis B vaccine in India

* Says Cipla launches Hepatitis B vaccine in India Source text - (http://bit.ly/2lUwkV6) Further company coverage:

Feb 17 2017

BRIEF-Cipla Ltd Dec-qtr consol profit up about 44 pct

* Consol net profit in Dec quarter last year was 2.61 billion rupees as per Ind-AS; consol net sales was 30.70 billion rupees

Feb 08 2017

India's Cipla Q3 profit up 43.7 pct, tops estimates

MUMBAI, Feb 8 Indian drugmaker Cipla Ltd reported a 43.7 percent jump in third-quarter net profit, beating analysts' expectations.

Feb 08 2017

More From Around the Web

Earnings vs. Estimates